THE 5-SECOND TRICK FOR BLUE PHARMACIES

a Change (drug minus placebo) in LS mean change from baseline not altered for sample size increase right after unblinded interim analysis.Concomitant use of CAPLYTA with average or potent CYP3A4 inhibitors will increase lumateperone exposure [see Scientific PHARMACOLOGY], which can raise the chance of adverse reactions.A horrific journey towards th